• Antibacterial Drug Use and Resistance in Psychiatric Hospita

  2026-04-22

  This study provides a comprehensive analysis of antibacterial drug use and bacterial resistance patterns in a psychiatric hospital during the COVID-19 epidemic. It highlights the distinct usage patterns and resistance challenges in psychiatric settings, emphasizing the need for enhanced surveillance and tailored antimicrobial stewardship.

• Scenario-Driven Best Practices with QNZ (EVP4593) for NF-κB

  2026-04-22

  This article addresses real-world laboratory challenges in cell-based NF-κB research, highlighting the evidence-backed performance and workflow compatibility of QNZ (EVP4593) (SKU A4217). Designed for biomedical scientists and technicians, it provides scenario-driven guidance and protocol optimization to ensure reliable results in inflammation and neurodegenerative disease models.

• Tofacitinib Citrate: Precision Tools for Translational Immun

  2026-04-21

  This thought-leadership article explores the mechanistic, translational, and strategic dimensions of Tofacitinib citrate (CP-690550 citrate) as a selective JAK3 inhibitor in immune regulation and inflammatory disorder research. Blending rigorous mechanistic insight with actionable guidance, it evaluates cardiovascular safety data, experimental protocols, and differentiation from standard product resources—providing translational researchers with an advanced framework for deploying Tofacitinib citrate in disease modeling and immune cell modulation.

• NU7441 (KU-57788): Empowering DNA Repair & Oncology Research

  2026-04-21

  NU7441 (KU-57788) stands out as a highly selective DNA-PK inhibitor, revolutionizing workflows in DNA repair, oncology, and cell cycle research. Discover data-driven protocol guidance, troubleshooting strategies, and insights from a landmark HIV latency study, all contextualized for translational research impact.

• Deferoxamine Mesylate: Iron Chelation, Ferroptosis, and Expe

  2026-04-20

  Explore how Deferoxamine mesylate, a powerful iron-chelating agent, enables advanced modeling of oxidative stress, ferroptosis, and hypoxia signaling in cancer and tissue protection research. This article uniquely dissects cross-pathway assay design and practical implications for next-generation biomedical workflows.

• Budesonide: Applied Workflows in Anti-Inflammatory Research

  2026-04-20

  Budesonide, a high-purity anti-inflammatory corticosteroid from APExBIO, is a cornerstone in advanced respiratory disease modeling. This guide translates breakthrough lung permeability research into actionable protocols, troubleshooting insights, and workflow enhancements for reliable, reproducible results.

• AR Heterogeneity Drives Distinct Therapy Responses in Prosta

  2026-04-19

  This study reveals that androgen receptor (AR) expression is highly heterogeneous in castration-resistant prostate cancer (CRPC) and directly influences tumor behavior and response to therapies like castration and enzalutamide. The findings provide a cellular basis for therapy resistance and identify new avenues for targeted intervention.

• Perphenazine: Dopamine D2 Receptor Antagonist in Translation

  2026-04-18

  Perphenazine’s unique receptor profile empowers researchers to probe both neuropharmacological signaling and host-pathogen interactions, offering robust, cross-domain applications. Recent evidence highlights its dual roles in inducing mitochondria-mediated cell death and enhancing macrophage antibacterial function, supporting its place as a high-impact research compound.

• Cyclosporin (SKU B8309): Reliable Immunosuppression in Cell

  2026-04-17

  This article offers scenario-driven, evidence-backed guidance on deploying Cyclosporin (SKU B8309) in cell viability and immunosuppression workflows. We address common pitfalls in assay reproducibility, protocol optimization, and vendor selection, with direct citations and practical recommendations. Researchers will gain actionable strategies to increase data reliability and interpretability using this validated reagent.

• Biotin-XX Tyramide Reagent: Precision in Cell Surface Labeli

  2026-04-16

  Biotin-XX Tyramide Reagent sets the benchmark for membrane-impermeant, HRP-catalyzed proximity labeling—enabling ultra-sensitive, selective detection of cell surface proteins. Its advanced chemistry facilitates robust tyramide signal amplification for even fleeting or low-abundance targets, as proven in groundbreaking synaptic trafficking studies.

• Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics

  2026-04-15

  Mdivi-1 stands out as a selective DRP1 inhibitor, empowering researchers to probe mitochondrial dynamics, apoptosis, and neuroprotection with precision and reproducibility. This article distills advanced workflows, data-driven troubleshooting, and unique insights from recent literature to maximize the reliability and impact of experiments using Mdivi-1 from APExBIO.

• Oridonin Modulates TAA-Induced Osteoclastogenesis via NF-κB/

  2026-04-14

  This study demonstrates that oridonin can counteract thioacetamide (TAA)-induced bone loss by inhibiting osteoclastogenesis through the MAPK/NF-κB pathway and promoting osteoblast differentiation. These findings point to new therapeutic strategies targeting inflammatory signaling in osteoporosis.

• Epoxomicin: Precision Proteasome Inhibitor for Cell Assays

  2026-04-13

  Epoxomicin stands out as a highly selective, irreversible proteasome inhibitor, empowering researchers to dissect protein degradation pathways with unmatched specificity. Its optimized protocols and robust performance in ubiquitin-proteasome pathway research make it a preferred choice for modeling inflammation, neurodegeneration, and viral pathogenesis.

• CD28-ARS2 Axis Controls PKM Splicing and CD8+ T Cell Metabol

  2026-04-12

  The reference study uncovers a novel CD28-ARS2 pathway that drives alternative splicing of pyruvate kinase (PKM), promoting PKM2 isoform expression and metabolic flexibility in CD8+ T cells. This mechanism enables enhanced antitumor immunity by supporting effector function, revealing new intervention points for immunometabolic research.

• SIRT3-SUMO Regulation of Treg Differentiation in Asthma via

  2026-04-12

  This study uncovers a mechanistic link between SIRT3-SUMO signaling, N-glycosylation, and Treg cell differentiation in asthma. By elucidating how fatty acid oxidation fuels N-glycosylation and promotes Treg development, the research provides a foundation for targeted immunometabolic interventions in asthma.

16324 records 1/1089 page Next 12345 下5页 Last page